Cipher Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Cipher Pharmaceuticals has a total shareholder equity of $98.9M and total debt of $40.0M, which brings its debt-to-equity ratio to 40.5%. Its total assets and total liabilities are $153.9M and $55.0M respectively. Cipher Pharmaceuticals's EBIT is $9.9M making its interest coverage ratio -6.9. It has cash and short-term investments of $9.5M.
Key information
40.5%
Debt to equity ratio
US$40.00m
Debt
| Interest coverage ratio | -6.9x |
| Cash | US$9.52m |
| Equity | US$98.86m |
| Total liabilities | US$55.00m |
| Total assets | US$153.86m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: PHE's short term assets ($29.1M) exceed its short term liabilities ($14.5M).
Long Term Liabilities: PHE's short term assets ($29.1M) do not cover its long term liabilities ($40.5M).
Debt to Equity History and Analysis
Debt Level: PHE's net debt to equity ratio (30.8%) is considered satisfactory.
Reducing Debt: PHE's debt to equity ratio has increased from 38.6% to 40.5% over the past 5 years.
Debt Coverage: PHE's debt is well covered by operating cash flow (32.7%).
Interest Coverage: PHE earns more interest than it pays, so coverage of interest payments is not a concern.